August 2020 - Market Week Member Showrooms & Exhibitor Showcases

Stand Together

Since its inception in 1993, more than $50 million has been donated towards first step breast cancer research.

back to Our Beneficiaries

Doctors & Shoe Biz Fight Against Cancer

The two forces plan to kick off a yearlong public awareness campaign with powerful tributes.

As seen in Footwear News – February 22, 2016

The Breast Cancer Research Foundation’s fight against its namesake disease has been a case of the shoe fitting very comfortably and wearing well as far as its partnership with the Fashion Footwear
Association of New York.

QVC Presents “FFANY Shoes on Sale” has contributed more than $4 million since 2003 that BCRF has invested in cancer research. Since its founding in 1993 by Evelyn H. Lauder, BCRF has raised more than half a billion dollars to fight breast cancer. It is the highest-rated breast cancer organization in the U.S., and the largest private funder of breast cancer research worldwide. This year, BCRF has awarded grants of $54 million to 240 scientists working in 13 nations. BCRF’s collaboration with FFANY kicks off this yearlong series of Footwear News tributes to FFANY’s cancer-research partners.

“The footwear industry has rallied around this cause with passion and dedication that is second to none,” says Myra J. Biblowit, who will mark 15 years in April as president of BCRF and friend to the late Evelyn, daughter-in- law of cosmetics magnate Estée Lauder. “Evelyn had what she called the ‘shoe gene,’ and she truly supported the footwear industry. She admired and appreciated FFANY, which continues to reciprocate the honor.”

“The footwear industry has been a powerful partner to BCRF in funding critical breast cancer research, and FFANY has been at the forefront of that drive,” says Leonard A. Lauder, chairman emeritus of The Estée Lauder Companies, Inc. “When, and not if, we eradicate breast cancer, it will be thanks… to dedicated partners like FFANY.”

Dr. Larry Norton, BCRF’s scientific director and medical director of the Evelyn H. Lauder Breast Center at Memorial Sloan Kettering Cancer Center in New York, emphasized the FFANY influence on new types of can- cer research. “FFANY’s BCRF grant is called the First Step Award because it is designed to support true medical innovation, ideas that despite being brilliant are new and hence untested,” Norton says. “It promotes the kind of work that leads to major advances.”

For a specific anticancer gain, Dr. Rachel Hazan, BCRF grantee and professor of pathology at Albert Einstein College of Medicine in New York, says that she was “grateful” to QVC Presents “FFANY Shoes on Sale,” because “it has allowed my lab to make major advances in research related to a type of breast cancer—called HER2+—that accounts for nearly 25% of all cases” as well as contribu- tions to better understand metastasis, the traveling of can- cer cells from one organ to another.

“The study of metastasis is a key focus of BCRF’s work,” says Marc Hurlbert, PhD, BCRF’s chief mission officer, “as are other critical areas including prevention programs, new treatments and quality of life issues to meet the needs of the patients.”

“Supporting breast cancer research is an important cause for our company,” said Alex Del Cielo, chairman and CEO of the Greenwich, CT-based Camuto Group, an important donor through FFANY. “We have always been committed to issues facing today’s women, and breast cancer has touched the lives of each and every one of us.” Added Louise Camuto, chief creative officer: “As a woman, I know so many individuals who have suffered and it is up to us to continue to partner as an industry to help support the goal of eradicating breast cancer.”

back to Our Beneficiaries